Recent agents targeting HIF-1α for cancer therapy

Journal of Cellular Biochemistry

Volumn 114, Issue 3, 2013, Pages 498-509

  Hu, Yaozhong ^a   Liu, Jing ^a   Huang, He ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

CANCER; CHEMICAL INHIBITORS; HIF 1 ; PROTEIN AND NUCLEIC ACID INHIBITORS; TARGETED THERAPY; VHH

Indexed keywords

2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 PHENETHYL ISOTHIOCYANATE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; APIGENIN; BORTEZOMIB; CETUXIMAB; CHETOMIN; ECHINOMYCIN; EVEROLIMUS; FLAVOPIRIDOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA ANTIBODY; LIFICIGUAT; METALLOTHIONEIN; PLEUROTIN; PX 12; RAPAMYCIN; RESVERATROL; ROMIDEPSIN; RX 0047; SILIBININ; SMALL INTERFERING RNA; TEMSIROLIMUS; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANGIOGENESIS; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA BINDING; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN TARGETING; REVIEW;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIXED FUNCTION OXYGENASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84872799328     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24390     Document Type: Review

References (89)

1. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L,. 2001. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: Protective role in apoptosis. J Biol Chem 276: 22368-22374.
2. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL,. 2007. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283.
3. Azzazy HM, Highsmith WE, Jr., 2002. Phage display technology: Clinical applications and recent innovations. Clin Biochem 35: 425-445.
4. Belozerov VE, Van Meir EG,. 2005. Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 16: 901-909.
5. Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C,. 2012. A Phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol 127: 55-62.
6. Bishayee A, Politis T, Darvesh AS,. 2010. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 36: 43-53.
7. Blagosklonny MV,. 2004. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 3: 1537-1542.
8. Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Sr., Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S,. 2012. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies. Cancer Chemother Pharmacol 69: 1657-1667.
9. Bowles DW, Jimeno A,. 2011. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drug 20: 507-518.
10. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V,. 2008. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 7: 1377-1385.
11. Cheng Y, Li W, Liu Y, Cheng HC, Ma J, Qiu L,. 2012. YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro, and in vivo under normoxic condition. Chin J Cancer 31: 248-256.
12. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW,. 2001. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61: 947-954.
13. Chun YS, Yeo EJ, Park JW,. 2004. Versatile pharmacological actions of YC-1: Anti-platelet to anticancer. Cancer Lett 207: 1-7.
14. Devisscher L, Hindryckx P, Olievier K, Peeters H, De Vos M, Laukens D,. 2011. Inverse correlation between metallothioneins and hypoxia-inducible factor 1 alpha in colonocytes and experimental colitis. Biochem Biophys Res Commun 416: 307-312.
15. Dikmen ZG, Gellert GC, Dogan P, Yoon H, Lee YB, Ahn CH, Shay JW,. 2008. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem 104: 985-994.
16. Dinkova-Kostova AT,. 2012. Chemoprotection against cancer by isothiocyanates: A focus on the animal models and the protective mechanisms. Top Curr Chem (in press).
17. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH,. 2005. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19: 342-353.
18. Fritz H, Seely D, Kennedy DA, Fernandes R, Cooley K, Fergusson D,. 2012. Green Tea and Lung Cancer: A Systematic Review. Integr Cancer Ther (in press).
19. Garcia-Maceira P, Mateo J,. 2009. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 28: 313-324.
20. Gorska M, Popowska U, Sielicka-Dudzin A, Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G, Wozniak F,. 2012. Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci 17: 2269-2277.
21. Groot AJ, Gort EH, van der Wall E, van Diest PJ, Vooijs M,. 2008. Conditional inactivation of HIF-1 using intrabodies. Cell Oncol 30: 397-409.
22. Groot AJ, Verheesen P, Westerlaken EJ, Gort EH, van der Groep P, Bovenschen N, van der Wall E, van Diest PJ, Shvarts A,. 2006. Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha. Lab Invest 86: 345-356.
23. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R,. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
24. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT,. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014.
25. Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee MO, Park H,. 2002. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90 kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62: 975-982.
26. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM,. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
27. Jacobs CS, Dervan PB,. 2009. Modifications at the C-terminus to improve pyrrole-imidazole polyamide activity in cell culture. J Med Chem 52: 7380-7388.
28. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK,. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369.
29. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL,. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771-17778.
30. Jones DT, Harris AL,. 2006. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 5: 2193-2202.
31. Jones DT, Pugh CW, Wigfield S, Stevens MF, Harris AL,. 2006. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 12: 5384-5394.
32. Jun HO, Kim Y, Kwon YW, Hong SS, Kim KW, Shin J, Kim TY,. 2007. Wondonin, a novel compound, inhibits hypoxia-induced angiogenesis through hypoxia-inducible factor 1 alpha. FEBS Lett 581: 4977-4982.
33. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D,. 2010. HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: Effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10: 605.
34. Kong D,. 2005. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65: 9047-9055.
35. Koukourakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, Giatromanolaki A, Sivridis E,. 2003. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: Dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status ? Anticancer Res 23: 1673-1680.
36. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM,. 2004. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43.
37. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H,. 2001. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 92: 1342-1351.
38. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM,. 2008. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7: 1472-1482.
39. Ledeboer AM, Bezemer S, de Hiaard JJ, Schaffers IM, Verrips CT, van Vliet C, Dusterhoft EM, Zoon P, Moineau S, Frenken LG,. 2002. Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. J Dairy Sci 85: 1376-1382.
40. Lee K, Kim HM,. 2011. A novel approach to cancer therapy using PX-478 as a HIF-1alpha inhibitor. Arch Pharm Res 34: 1583-1585.
41. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL,. 2009. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106: 2353-2358.
42. Li SH, Shin DH, Chun YS, Lee MK, Kim MS, Park JW,. 2008. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther 7: 3729-3738.
43. Li Y, Ye D,. 2010. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Target 10: 782-796.
44. Li Y, Zhao X, Tang H, Zhong Z, Zhang L, Xu R, Li S, Wang Y,. 2012. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells. Urol Int 88: 95-101.
45. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW,. 2010. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38: 864-878.
46. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z,. 2005. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441.
47. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P,. 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375.
48. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H,. 2002. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62: 2478-2482.
49. Mie Lee, Kim Y, Kim SH, Jin HS, Son M, Nakajima H, Jeong Kwon H, Kim KW,. 2003. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300: 241-246.
50. Mizuno T, Nagao M, Yamada Y, Narikiyo M, Ueno M, Miyagishi M, Taira K, Nakajima Y,. 2006. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13: 131-140.
51. Newcomb EW, Ali MA, Schnee T, Lan L, Lukyanov Y, Fowkes M, Miller DC, Zagzag D,. 2005. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol 7: 225-235.
52. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Jr., Dervan PB,. 2004. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA 101: 16768-16773.
53. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BK, Lee HY,. 2007. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Lett 258: 63-69.
54. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R,. 2006. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814-8821.
55. Rahbarizadeh F, Rasaee MJ, Forouzandeh Moghadam, M, Allameh AA, Sadroddiny E,. 2004. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid Hybridomics 23: 151-159.
56. Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD,. 2011. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67: 503-509.
57. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J,. 2003. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278: 14013-14019.
58. Semenza GL,. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
59. Semenza GL,. 2007. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007: cm8
60. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A,. 1997. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51: 553-555.
61. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK,. 2009. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8: 1596-15605.
62. Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P,. 2006. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: A clinical phase I study. Nutr Cancer 55: 53-62.
63. Shin DH, Chun YS, Lee DS, Huang LE, Park JW,. 2008. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111: 3131-3136.
64. Shinohara K, Bando T, Sugiyama H,. 2010. Anticancer activities of alkylating pyrrole-imidazole polyamides with specific sequence recognition. Anticancer Drugs 21: 228-2242.
65. Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M,. 1996. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3: 752-757.
66. Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K, Tegoni M, Cambillau C,. 2000. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 39: 1217-1222.
67. Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, Fleischer M, Schwab F, Baier K, Einsele H, Flentje M, Vordermark D,. 2007. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer 7: 213.
68. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kuo SC, Teng CM,. 2007. YC-1 inhibits HIF-1 expression in prostate cancer cells: Contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26: 3941-3951.
69. Takenaga K,. 2011. Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci 16: 31-48.
70. To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE,. 2006. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J 25: 4784-4794.
71. Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X,. 2011. Nanobodies®: New ammunition to battle viruses. Antiviral Res 92: 389-407.
72. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R,. 2008. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14: 3589-3597.
73. Vlaminck B, Toffoli S, Ghislain B, Demazy C, Raes M, Michiels C,. 2007. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J 274: 5533-5542.
74. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ,. 2006. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8: 394-401.
75. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
76. Wang GL, Semenza GL,. 1993. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268: 21513-21518.
77. Wang XH, Cavell BE, Syed Alwi, SS, Packham G,., 2009. Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. Biochem Pharmacol 78: 261-272.
78. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G,. 2004. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3: 233-244.
79. Welsh SJ, Bellamy WT, Briehl MM, Powis G,. 2002. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095.
80. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G,. 2003. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243.
81. Xia Y, Choi H-K, Lee K,. 2012. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49: 24-40.
82. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, Lv YM, Yang CX, Liu YW,. 2006. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 25: 593-599.
83. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW,. 2003. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95: 516-525.
84. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS, Park JW,. 2006. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107: 916-923.
85. Yip YL, Ward RL,. 2002. Application of phage display technology to cancer research. Curr Pharm Biotechnol 3: 29-43.
86. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD,., 2006. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5: 1227-1238.
87. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD,. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474.
88. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL,. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
89. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR,. 2011. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drug 29: 340-346.